NEW YORK (GenomeWeb News) – Diagnostic test provider Quidel said last week that it has signed an exclusive, worldwide license for the MChip microarray-based influenza detection technology developed by scientists at the University of Colorado and the US Centers for Disease Control and Prevention.
 
The company said it plans to develop and market molecular-based diagnostic tests based on the MChip for use in pandemic surveillance, as a tool for clinical labs, and for point-of-care use in physicians’ offices.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.